Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
41 pending office actions • 6 art units • 24 examiners • 0 of 41 (0%) have an AI response strategy ready • 27 patents granted in the last 365 days
Alnylam Pharmaceuticals Inc. maintains 41 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 24 distinct examiners and 6 distinct art units. The presence of 24 examiners and 6 art units indicates that multiple examiners are often working within the same specialized groups to review the company's filings. This structure shows a volume of activity within a set of technical disciplines.
HUDSON, AMY ROSE serves as the busiest examiner for this portfolio, currently overseeing 5 busiest examiner pending actions. This concentration represents a portion of the total 41 pending office actions managed by the 24 distinct examiners. The diversity of examiners suggests that the portfolio faces a range of individual examination styles across its 6 distinct art units. Navigating the distinct examiners requires a prosecution strategy that can adapt to the different tendencies of the various individuals. The presence of the distinct art units further implies that the company's biotechnology research is being evaluated by several specialized technical teams.
Based on the USPTO statutory response window for each pending office action. 15 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 15 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 8 (20%) |
| §103 only | 11 (27%) |
| Double-patenting + other | 10 (24%) |
| Multi-statute (no §101) | 11 (27%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUDSON, AMY ROSE | 5 | 74.9% | +11.5% |
| TRAN, CHRISTINA L | 5 | 51.6% | +48.2% |
| SULLIVAN, STEPHANIE LAUREN | 3 | 58.1% | +40.9% |
| GIBBS, TERRA C | 3 | 63.7% | +10.3% |
| ZAHORIK, AMANDA MARY | 2 | 57.8% | +49.0% |
| VYAS, KEYUR ANILKUMAR | 2 | 49.4% | +60.8% |
| YU, DELPHINUS DOU YI | 2 | 33.3% | +0.0% |
| ALLEN, SARAH ELIZABETH | 2 | 57.1% | +50.0% |
| POLIAKOVA-GEORGAN, EKATERINA | 2 | 64.0% | +18.0% |
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773508 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | VYAS, KEYUR ANILKUMAR | 85d overdue |
| 18324191 | METHODS AND COMPOSITIONS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | TRAN, CHRISTINA L | 52d overdue |
| 18637183 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | GIBBS, TERRA C | 9d overdue |
| 17802004 | G PROTEIN-COUPLED RECEPTOR 146 (GPR146) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | PERSONS, JENNA L | 30d |
| 17611761 | ORAL DELIVERY OF OLIGONUCLEOTIDES | TRAN, CHRISTINA L | 49d |
| 18761504 | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE | ZAHORIK, AMANDA MARY | — |
| 18623281 | RENAL INJURY BIOMARKERS AS BIOMARKERS FOR ACUTE HEPATIC PORPHYRIA (AHP) | BRETZ, COREY LANE | — |
| 18423377 | 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | GROOMS, TIFFANY NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17683423 | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 110d overdue |
| 17773508 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | VYAS, KEYUR ANILKUMAR | 85d overdue |
| 18324191 | METHODS AND COMPOSITIONS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | TRAN, CHRISTINA L | 52d overdue |
| 18376217 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 38d overdue |
| 17995035 | MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | SULLIVAN, STEPHANIE LAUREN | 32d overdue |
| 18637183 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | GIBBS, TERRA C | 9d overdue |
| 17974596 | APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | TRAN, CHRISTINA L | 4d overdue |
| 18302855 | METHODS AND COMPOSITIONS FOR TREATING PRIMARY HYPEROXALURIA | POLIAKOVA-GEORGAN, EKATERINA | 14d |
| Art Unit | Apps |
|---|---|
| 1637 | 14 |
| 1636 | 9 |
| 1635 | 6 |
| 1653 | 1 |
| 1691 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18978602 | SNCA-TARGETING SIRNA COMPOSITIONS FOR TREATING SNCA-ASSOCIATED DISEASE | SULLIVAN, STEPHANIE LAUREN | 1635 | §103Other | Non-Final OA | 33d | Pending | Dec 12, 2024 |
| 18761504 | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE | ZAHORIK, AMANDA MARY | — | §102§103§112 | Non-Final OA | — | Pending | Jul 02, 2024 |
| 18637183 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | GIBBS, TERRA C | 1635 | §101§102§103§112 | Final Rejection | 9d overdue | Pending | Apr 16, 2024 |
| 18623281 | RENAL INJURY BIOMARKERS AS BIOMARKERS FOR ACUTE HEPATIC PORPHYRIA (AHP) | BRETZ, COREY LANE | — | §102§103§112DP | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18613537 | 3'-OH RNA-CONTAINING OLIGONUCLEOTIDE DEPROTECTION | CHO, DAVID H | — | §102§103§112DP | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18581511 | BETA-CATENIN (CTNNB1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | VYAS, KEYUR ANILKUMAR | 1637 | §103Other | Non-Final OA | 79d | Pending | Feb 20, 2024 |
| 18434928 | COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | HUDSON, AMY ROSE | 1636 | §103 | Final Rejection | — | Pending | Feb 07, 2024 |
| 18423377 | 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | GROOMS, TIFFANY NICOLE | — | §101§103§112 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18577948 | MULTIPLEXING TARGETING LIGANDS THROUGH CLICK CHEMISTRY AT THE ANOMERIC SITE OF SUGARS | LEE, HOI YAN NMN | — | §102§103§112Other | Non-Final OA | — | Pending | Jan 09, 2024 |
| 18577377 | BIS-RNAI COMPOUNDS FOR CNS DELIVERY | ZAHORIK, AMANDA MARY | — | §103 | Non-Final OA | — | Pending | Jan 08, 2024 |
| 18403862 | METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING OR AT RISK OF DEVELOPING A NON-PRIMARY HYPEROXALURIA DISEASE OR DISORDER | WHITEMAN, BRIAN A | — | §102§103§112DP | Non-Final OA | — | Pending | Jan 04, 2024 |
| 18542950 | METHODS AND COMPOSITIONS FOR TREATING AN ANGIOTENSINOGEN- (AGT-) ASSOCIATED DISORDER | GIBBS, TERRA C | — | §103§112DP | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18525922 | PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | YU, DELPHINUS DOU YI | — | §101§102§103 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18389245 | SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ZARA, JANE J | 1637 | §101§103 | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18556180 | REDIRECTING RISC FOR RNA EDITING | ALLEN, SARAH ELIZABETH | 1653 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18376217 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | §112DP | Non-Final OA | 38d overdue | Pending | Oct 03, 2023 |
| 18373397 | PROLINE DEHYDROGENASE 2 (PRODH2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103 | Non-Final OA | — | Pending | Sep 27, 2023 |
| 18551668 | ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | SU-TOBON, QIWEN NMN | 1636 | §101§103§112 | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18243133 | GLYCOGEN SYNTHASE KINASE 3 ALPHA (GSK3 ALPHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | TRAN, CHRISTINA L | 1637 | §101§103§112 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18548634 | DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA | HUDSON, AMY ROSE | 1636 | §102§103§112 | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18236437 | PRION PROTEIN (PRNP) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | YU, DELPHINUS DOU YI | 1636 | §103DP | Non-Final OA | — | Pending | Aug 22, 2023 |
| 18547102 | FOLLICULIN iRNA COMPOSITIONS AND METHODS THEREOF | KONOPKA, CATHERINE ANNE | 1636 | §101§102§103§112DP | Non-Final OA | — | Pending | Aug 18, 2023 |
| 18215849 | COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | GIBBS, TERRA C | 1635 | §101 | Non-Final OA | — | Pending | Jun 29, 2023 |
| 18324191 | METHODS AND COMPOSITIONS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | TRAN, CHRISTINA L | 1637 | §103§112Other | Final Rejection | 52d overdue | Pending | May 26, 2023 |
| 18136386 | MUCIN 5B (MUC5B) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | §102§103§112 | Non-Final OA | — | Pending | Apr 19, 2023 |
| 18302855 | METHODS AND COMPOSITIONS FOR TREATING PRIMARY HYPEROXALURIA | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§103§112DP | Final Rejection | 14d | Pending | Apr 19, 2023 |
| 18301089 | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | CHONG, KIMBERLY | 1636 | §103§112DP | Final Rejection | 127d overdue | Pending | Apr 14, 2023 |
| 18131892 | SUPEROXIDE DISMUTASE 1 (SOD1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SUPEROXIDE DISMUTASE 1- (SOD1-) ASSOCIATED NEURODEGENERATIVE DISEASES | ANGELL, JON E | 1637 | §102§103 | Non-Final OA | — | Pending | Apr 07, 2023 |
| 17773508 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | VYAS, KEYUR ANILKUMAR | 1637 | §103§112 | Final Rejection | 85d overdue | Pending | Feb 09, 2023 |
| 18015202 | Circular siRNAs | TRAN, CHRISTINA L | 1637 | §103 | Final Rejection | — | Pending | Jan 09, 2023 |
| 18001813 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | SULLIVAN, STEPHANIE LAUREN | 1635 | §102§103 | Final Rejection | — | Pending | Dec 14, 2022 |
| 17974596 | APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | TRAN, CHRISTINA L | 1637 | §103 | Final Rejection | 4d overdue | Pending | Oct 27, 2022 |
| 17995568 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | MEYERING, SHABANA SHABBEER | 1635 | §103 | Final Rejection | — | Pending | Oct 05, 2022 |
| 17995035 | MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | SULLIVAN, STEPHANIE LAUREN | 1635 | §103 | Final Rejection | 32d overdue | Pending | Sep 29, 2022 |
| 17802004 | G PROTEIN-COUPLED RECEPTOR 146 (GPR146) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | PERSONS, JENNA L | 1637 | §103§112 | Non-Final OA | 30d | Pending | Aug 24, 2022 |
| 17779706 | SYNTHESIS OF 3 -RNA OLIGONUCLEOTIDES | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | 26d overdue | Pending | May 25, 2022 |
| 17683423 | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | §112DP | Final Rejection | 110d overdue | Pending | Mar 01, 2022 |
| 17668413 | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALLEN, SARAH ELIZABETH | 1637 | §102§103§112 | Final Rejection | — | Pending | Feb 10, 2022 |
| 17619633 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | MCKILLOP, JOHN CHARLES | 1637 | §112DP | Final Rejection | — | Pending | Dec 16, 2021 |
| 17611761 | ORAL DELIVERY OF OLIGONUCLEOTIDES | TRAN, CHRISTINA L | 1637 | §103§112Other | Final Rejection | 49d | Pending | Nov 16, 2021 |
| 17250952 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BRANDSEN, BENJAMIN MICHAEL | 1693 | §103 | Non-Final OA | 230d overdue | Pending | Apr 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial